M&A Deal Summary |
|
|---|---|
| Date | 2017-03-28 |
| Target | ALT Technologies |
| Sector | Automotive |
| Buyer(s) | GIMV |
| Sellers(s) | Standard Investment Management |
| Deal Type | Secondary Buyout |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 108 of 170 |
| Sector: Automotive M&A | 4 of 5 |
| Type: Secondary Buyout M&A Deals | 16 of 28 |
| Country: Netherlands M&A | 31 of 42 |
| Year: 2017 M&A | 2 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-01-02 |
Breath Therapeutics
Munich, Germany Breath Therapeutics is a clinical stage biopharmaceutical company specializing in advanced inhaled therapeutics for severe respiratory diseases with a high unmet medical need. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-05-02 |
Imcheck Therapeutics
Marseilles, France ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2004 |
| PE ASSETS | 90M EUR |
| Size | Small |
| Type | Sector Agnostic |
Standard Investment is a Dutch private equity firm focused on small to mid-sized investment opportunities in the Netherlands and Belgium. The Firm targets companies generating €20 to €200 million of revenue and valued up to €100 million. Standard Investment prefers majority investment situations and looks for businesses with growth and/or improvement potential. Standard Investment was formed in 2004 and has offices in Amsterdam and Brussels.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 11 |
| Sector: Automotive M&A | 3 of 3 |
| Type: Secondary Buyout M&A Deals | 2 of 2 |
| Country: Netherlands M&A | 5 of 9 |
| Year: 2017 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-12-23 |
Jumbo Groenewegen
Helmond, Netherlands Jumbo Groenewegen designs, produces and sells trailers and semi-trailers for demanding customers on a domestic and international level. Jumbo Groenewegen was founded in 1927 and is based in Helmond, Netherlands. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-04-13 |
Sekura Cabins
Randers, Denmark Sekura Cabins specializes in the development and production of safe and low-noise operator cabs for off-highway vehicles, primarily for mining and forestry. Sekura often develops its solutions in close collaboration with its customers, with whom the company has often worked for decades. Sekura Cabins was founded in 1957 and is based in Randers, Denmark. |
Buy | - |
